Charles Schwab Investment Management Inc. Has $23.40 Million Stock Position in iRhythm Technologies, Inc. (NASDAQ:IRTC)

Charles Schwab Investment Management Inc. increased its stake in iRhythm Technologies, Inc. (NASDAQ:IRTC - Free Report) by 1.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 259,494 shares of the company's stock after acquiring an additional 3,791 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.83% of iRhythm Technologies worth $23,399,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the stock. Versor Investments LP acquired a new position in shares of iRhythm Technologies in the 4th quarter worth $251,000. Bank of New York Mellon Corp grew its holdings in shares of iRhythm Technologies by 23.2% in the 4th quarter. Bank of New York Mellon Corp now owns 491,485 shares of the company's stock worth $44,317,000 after acquiring an additional 92,591 shares during the last quarter. Handelsbanken Fonder AB grew its holdings in shares of iRhythm Technologies by 5.9% in the 4th quarter. Handelsbanken Fonder AB now owns 10,839 shares of the company's stock worth $977,000 after acquiring an additional 600 shares during the last quarter. Alberta Investment Management Corp grew its holdings in shares of iRhythm Technologies by 53.3% during the fourth quarter. Alberta Investment Management Corp now owns 145,166 shares of the company's stock valued at $13,090,000 after buying an additional 50,452 shares in the last quarter. Finally, Peregrine Capital Management LLC grew its holdings in shares of iRhythm Technologies by 1.1% during the fourth quarter. Peregrine Capital Management LLC now owns 99,153 shares of the company's stock valued at $8,941,000 after buying an additional 1,110 shares in the last quarter.

Remove Ads

iRhythm Technologies Trading Up 0.1 %

IRTC stock traded up $0.15 during midday trading on Friday, hitting $104.49. 400,911 shares of the company's stock were exchanged, compared to its average volume of 459,784. The stock's fifty day moving average price is $107.76 and its 200-day moving average price is $88.62. The company has a debt-to-equity ratio of 9.00, a quick ratio of 6.12 and a current ratio of 6.27. The company has a market cap of $3.28 billion, a PE ratio of -28.71 and a beta of 1.36. iRhythm Technologies, Inc. has a one year low of $55.92 and a one year high of $128.52.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.30. iRhythm Technologies had a negative return on equity of 118.83% and a negative net margin of 19.14%. The firm had revenue of $164.33 million for the quarter, compared to the consensus estimate of $158.30 million. Research analysts predict that iRhythm Technologies, Inc. will post -1.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IRTC has been the topic of a number of research analyst reports. Truist Financial lifted their price target on iRhythm Technologies from $111.00 to $145.00 and gave the company a "buy" rating in a report on Friday, February 21st. The Goldman Sachs Group lifted their price target on iRhythm Technologies from $91.00 to $124.00 and gave the company a "neutral" rating in a report on Monday, February 24th. StockNews.com upgraded iRhythm Technologies from a "sell" rating to a "hold" rating in a report on Monday, February 24th. Oppenheimer lifted their price target on iRhythm Technologies from $105.00 to $120.00 and gave the company an "outperform" rating in a report on Wednesday, January 8th. Finally, Wells Fargo & Company lifted their price objective on iRhythm Technologies from $86.00 to $104.00 and gave the company an "equal weight" rating in a research report on Friday, February 21st. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, iRhythm Technologies presently has a consensus rating of "Moderate Buy" and an average price target of $119.73.

iRhythm Technologies Profile

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.